Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase i clinical trial

Journal of Infectious Diseases

Volumn 211, Issue 4, 2015, Pages 549-557

  Sarwar, Uzma N ^a   Costner, Pamela ^a   Enama, Mary E ^a   Berkowitz, Nina ^a   Hu, Zonghui ^a   Hendel, Cynthia S ^a   Sitar, Sandra ^a   Plummer, Sarah ^a   Mulangu, Sabue ^a   Bailer, Robert T ^a   Koup, Richard A ^a   Mascola, John R ^a   Nabel, Gary J ^a   Sullivan, Nancy J ^a   Graham, Barney S ^a   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

DNA; ebola; ebolavirus; filovirus; marburg; marburgvirus; vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VIRUS GLYCOPROTEIN; CYTOKINE; EBOLA VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY TITER; ARTICLE; BODY TEMPERATURE DISORDER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; DIZZINESS; DRUG DELIVERY DEVICE; DRUG SAFETY; DRUG TOLERABILITY; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MALAISE; MALE; MARBURG VIRUS; MYALGIA; NAUSEA; NEEDLE FREE INJECTION MANAGEMENT SYSTEM; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PYURIA; UNSPECIFIED SIDE EFFECT; WILD TYPE; BLOOD; CLINICAL TRIAL; EBOLAVIRUS; GENETICS; IMMUNOLOGY; MARBURGVIRUS; MIDDLE AGED; T LYMPHOCYTE; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; CYTOKINES; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; MALE; MARBURGVIRUS; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, DNA; VIRAL VACCINES; YOUNG ADULT;

EID: 84922473334     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu511     Document Type: Article

References (26)

1. Sanchez A, Kiley MP, Klenk HD, Feldmann H. Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol 1992; 73(pt 2):347-57.
2. Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol 2003; 33:583-95.
3. Dessen A, Volchkov V, Dolnik O, Klenk HD, Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J 2000; 19:4228-36.
4. Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease): Outbreaks. Known cases and outbreaks of Ebola hemorrhagic fever, in chronological order. Available at: http://www.cdc.gov/vhf/ebola/outbreaks/index.html. Accessed 12 August 2014.
5. Sarwar UN, Sitar S, Ledgerwood JE. Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. Travel Med Infect Dis 2011; 9:126-34.
6. Centers for Disease Control and Prevention. 2014 Ebola outbreak in West Africa. http://www.cdc.gov/vhf/ebola/outbreaks/guinea/. Accessed 12 August 2014.
7. Centers for Disease Control and Prevention. Marburg hemorrhagic fever (Marburg HF). http://www.cdc.gov/vhf/marburg/index.html. Accessed 12 August 2014.
8. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
9. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated re-combinant vaccine. J Virol 2006; 80:9659-66.
10. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexpo-sure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404.
11. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
12. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77.
13. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recom-binant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13.
14. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of non-human primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177.
15. Division of AIDS Table for Grading the Severity of Adverse Events (December 2004). Available at: http://www.niaid.nih.gov/LabsAnd Resources/resources/DAIDSClinRsrch/Documents/daidsaegrading table.pdf.
16. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004; 78:5642-50.
17. Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005; 79:8828-34.
18. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-92.
19. Ledgerwood JE, Hu Z, Gordon IJ, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7.
20. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011; 203:1396-404.
21. Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008; 26: 6338-43.
22. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immuno-genicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-60.
23. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196:1732-40.
24. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24.
25. Fausther-Bovendo H, Mulangu S, Sullivan NJ. Ebolavirus vaccines for humans and apes. Curr Opin Virol 2012; 2:324-9.
26. + cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17:1128-31.